Greenwich LifeSciences to Present at Multiple Investor Conferences, Including H.C. Wainwright Global Life Sciences and BIO-Europe Spring Conferences
STAFFORD, Texas--(BUSINESS WIRE)-- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Snehal Patel, CEO of Greenwich LifeSciences, will participate in multiple virtual investor conferences in March 2021.
A previously recorded webcast of the Company’s presentation is available on the Company’s website here.
H.C. Wainwright Global Life Sciences Conference 2021:
The Company will be participating in the H.C. Wainwright Global Life Sciences Conference with a virtual presentation that will be available on demand beginning on March 9th. In addition, the Company will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website at: https://hcwevents.com/globalconference/
Landmark Health Innovations 2021:
The Company will be participating in the Landmark Health Innovations Conference with a live virtual presentation on March 11th at approximately 3:40 pm EST to High Net Worth and Family Office conference participants in this by-invitation event. Landmark’s Health Innovations 2021, a two-day virtual event, will feature virtual presentations from a roster of select companies, an expert keynote address, and an "Investor Roundtable" session to introduce Landmark’s investors. For more information, please visit the conference website at: https://www.landmarkangels.com/events
BIO-Europe Spring 2021:
The Company will be participating in the BIO-Europe Spring partnering event from March 22-25 with an on-demand presentation available to conference participants. The BIO-Europe Spring 2021 program content includes business development, therapeutic areas, startup innovations, digital health, and scheduled one-on-one meetings. For more information, please visit the conference website at: https://informaconnect.com/bioeurope-spring/
Benzinga Biotech Small-Cap Conference 2021:
The Company will be participating in the Benzinga Biotech Small-Cap Conference with a live 15 minute virtual presentation on March 25th to Benzinga’s small-cap investors followed by Q&A. The Company may also participate in a 30 minute oncology panel on March 25th and on Benzinga’s YouTube "PowerHour" show scheduled for March 11th. In addition, Benzinga may also publish an article on the Company. For more information, please visit the conference website at: https://www.benzinga.com/events/small-cap/
About Breast Cancer and HER2/neu Positivity
One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. HER2/neu (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
Forward-Looking Statement Disclaimer
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.
Investor & Public Relations Contact for Greenwich LifeSciences
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Cell: (407) 491-4498
Source: Greenwich LifeSciences, Inc.
Released March 2, 2021